Recombinant Human DERP2 protein

Der p 2 (Dermatophagoides pteronyssinus allergen 2) is a major allergen produced by house dust mites (HDMs), primarily implicated in triggering allergic responses such as asthma, rhinitis, and atopic dermatitis. As a member of the MD-2-related lipid-recognition protein family, Der p 2 exhibits structural homology to MD-2. a component of the Toll-like receptor 4 (TLR4) complex, enabling it to bind lipopolysaccharides (LPS) and modulate innate immune signaling. This dual functionality—acting as both an allergen and an immune adjuvant—contributes to its high allergenic potency.

Recombinant Der p 2 (rDer p 2) is engineered through heterologous expression systems (e.g., E. coli, yeast) to replicate the native protein's immunogenic properties while ensuring purity and batch consistency. Unlike natural Der p 2 extracted from mites, recombinant production eliminates contamination risks from other mite-derived allergens or microbial components, enhancing its utility in research and diagnostics. Its well-characterized IgE-binding epitopes make it valuable for component-resolved allergy diagnostics, enabling precise identification of Der p 2-specific sensitization in patients.

Additionally, rDer p 2 is pivotal in developing allergen-specific immunotherapies (AIT), including hypoallergenic variants or fusion proteins designed to reduce adverse effects while retaining immunomodulatory efficacy. Structural studies of rDer p 2 have elucidated mechanisms underlying its cross-reactivity with other mite allergens and its role in Th2-biased immune responses. Ongoing research focuses on leveraging recombinant technology to improve therapeutic safety profiles and explore novel vaccine platforms targeting HDM allergies.